



Kilitch Drugs (India) Ltd.

November 7, 2018

To
Department of Corporate Services
BSE Limited
P. J. Towers, Dalal Street
Fort, Mumbai - 400 001
Scrip Code: **BSE - 524500**

To
Corporate Listing Department
National Stock Exchange of India Ltd
Exchange Plaza, Plot No.C-1, G Block,
BKC, Bandra (E), Mumbai 400 051
Scrip Code: **NSE - KILITCH**

Sub: **Outcome of Board Meeting held on November 7, 2018**

Dear Sir/Madam,

In continuation to our letter dated October 31, 2018, we wish to inform you that pursuant to Regulation 33 and Regulation 30 read with Para A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the Board of Directors of the company, at its meeting held today i.e. 7th November, 2018, have

1. Considered & approved the Un-audited financial results of the company for the quarter/half year ended September 30, 2018.
2. Considered and Noted the Resignation of Mr. Shailesh Chheda as a Director of the Company with effect from 1st October, 2018.
3. Approved the re-appointment of Mrs. Mira Mehta as a Whole-time Director of the Company.

In this connection please find enclosed the copy of Un-audited Standalone financial Results of the Company for the quarter/half year ended 30th September, 2018 along with Limited Review Report by the Statutory Auditors of the Company as "Annexure-I".

The meeting commenced at 10:00 A.M. and concluded at 07.00 P.M.

The above is for information and dissemination to the public at large.

Thanking You,

Yours Faithfully,
For **Kilitch Drugs (India) Limited**

Mukund Mehta
Manging Director
DIN: 00147876



Encl: as above

A. M. GHELANI & COMPANY
CHARTERED ACCOUNTANTS

224, Champaklal Industrial Estate
Sion-Koliwada Road, Sion (East),
Mumbai - 400 022.
Tel : 2402 4909 / 8739
Fax : 2407 1138
E-mail : amghelaniandco@gmail.com

AJIT M. GHELANI
B.Com (Hons), F.C.A., GRAD. C.W.A.

CHINTAN A. GHELANI
B.Com (Hons), F.C.A., C.S

To,
The Board of Directors
Kilitch Drugs (India) Limited


LIMITED REVIEW REPORT OF THE UNAUDITED STANDALONE RESULTS OF KILITCH DRUGS (INDIA) LIMITED FOR THE QUARTER/HALF YEAR ENDED 30TH SEPTEMBER, 2018

1. We have reviewed the accompanying statement of unaudited standalone financial results of KILITCH DRUGS (INDIA) LIMITED (the 'Company') for the quarter and half ended 30th September, 2018 being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.
2. The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting, prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of Companies (Indian Accounting Standards) Rules, 2015 and SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016 is the responsibility of the Company's management and has been approved by the Board of Directors of the company. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with the recognition and measurement principles laid down in applicable Indian Accounting Standards ('Ind AS') specifies under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For A. M. Ghelani & Company

Chartered Accountants

FRN: 103173W


Chintan Ghelani

Partner

Membership No.: 104391



Place : Mumbai

Dated : 7th November, 2018

Encl: Unaudited financial results for the quarter & half year ended 30th September, 2018.

KILITCH DRUGS (INDIA) LIMITED

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2018

Regd. Office:- C-301/2, MIDC, TTC Industrial Area, Pawane Village, Thane-400701

Tel No: 022- 61214100, Email id: info@kilitch.com, Website: www.kilitch.com

(Rs.in Lakhs)

Sr. No.	Particulars	STANDALONE					
		Three Months Ended			Six months Ended		Year Ended
		30-09-2018	30-06-2018	30/9/2017	30-09-2018	30-09-2017	31/03/2018
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
1	Income from operations						
	Net Sales/ Income from operations	2,672.00	2,797.34	1,494.78	5,469.34	2,170.60	5,045.78
	Other Income	188.69	236.77	156.71	425.46	177.37	277.91
	Total Income from Operations	2,860.69	3,034.11	1,651.49	5,894.80	2,347.97	5,323.69
2	Expenses						
	(a) Cost of Materials Consumed	1,635.05	1,765.53	909.67	3,400.58	1,261.09	2,635.11
	(b) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	18.42	(55.31)	(124.29)	(36.89)	(166.65)	(44.20)
	(c) Employee Benefit Expenses	143.74	136.37	100.93	280.11	200.79	421.93
	(d) Finance Cost	-	-	-	-	-	-
	(e) Depreciation and Amortisation Expenses	29.31	26.01	29.75	55.32	57.79	119.23
	(f) Export Product Registration/Commission	242.02	64.06	64.17	306.08	95.51	339.43
	(g) Other Expenses	179.77	563.35	431.82	743.12	681.31	1,136.55
	Total Expenses	2,248.31	2,500.01	1,412.05	4,748.32	2,129.84	4,608.05
3	Profit / (Loss) before Exceptional items (1-2)	612.38	534.10	239.44	1,146.48	218.13	715.64
4	Exceptional Items	-	-	-	-	-	-
5	Profit / (Loss) from ordinary activities before tax (3+4)	612.38	534.10	239.44	1,146.48	218.13	715.64
6	Tax Expenses:						
	Current Tax	146.88	59.12	10.00	206.00	10.00	33.48
	Deferred Tax	16.85	58.07	6.14	74.92	(3.61)	62.57
7	Net Profit / (Loss) after Tax for the period from Continuing Operations (5-6)	448.65	416.91	223.30	865.56	211.74	619.59
8	Other Comprehensive Income (after tax)	(108.05)	(29.59)	(88.83)	(137.64)	(26.71)	66.81
9	Total Comprehensive Income (after taxes) (7+8)	340.60	387.32	134.47	727.92	185.03	686.40
10	Paid-Up equity share capital (Face Value Rs 10 per share)	1,535.52	1,373.18	1,323.18	1,535.52	1,323.18	1,373.18
11	Other Equity						11,746.37
12	Earnings per share						
	(a) Basic (not annualised)	3.20	3.04	1.69	6.24	1.60	4.68
	(b) Diluted (not annualised)	3.20	2.72	1.68	5.92	1.59	4.40

Notes:

- The above results as reviewed by the Audit Committee have been taken on record by the Board of Directors at their meeting held on 7th November, 2018.
- The statement has been prepared in accordance with companies (Indian Accounting Standards) Rule, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- During the quarter, 16,00,000 Equity Share warrants, which were issued to the promoters of the company on a preferential basis in September, 2017, at the issue price of Rs. 59 per warrant, have been converted into 16,00,000 Equity Shares of Rs. 10/- each at a premium of Rs. 49 per share.
- The company has issued 23,414 Equity Shares under the ESOP scheme at an exercise price of Rs. 10 per equity share during the quarter ended 30th September, 2018
- The Company is predominantly engaged in the business of Pharmaceuticals, whose results are reviewed regularly by chief operating decision maker for making decisions about resource allocation and performance assessment. As such, there are no separate reporting segments as per Ind-AS108.
- The IND AS 115 Revenue from Contract with customers, mandatory for reporting periods beginning on or after April 1, 2018, replaces the existing revenue recognition requirements. The application of IND AS 115 has not impacted the company's accounting for recognition of revenue.
- The figures for the corresponding previous periods have been restated/regrouped, wherever necessary, to make them comparable with the current periods.

For and on behalf of the Board

Mukund P. Mehta
Managing Director



Place: Mumbai
Date: 7th November, 2018


KILITCH DRUGS (INDIA) LIMITED

STATEMENT OF ASSETS AND LIABILITIES

(Rs. in Lakhs)

Particulars	STANDALONE	
	As at 30th September, 2018	As at 31st March, 2018
ASSETS		
Non-current assets		
Property, Plant and Equipment	790.20	732.81
Capital work-in-progress	-	-
Other Intangible Assets	3.49	2.35
Financial assets		
- Investments	7,166.39	7,024.52
- Loans/Advances	815.37	358.79
- Other Financial Assets	105.00	78.97
Deferred tax assets (Net)	79.87	154.79
(A)	8,960.32	8,352.23
Current Assets		
Inventories	392.30	279.64
Financial assets		
- Investments	3,864.47	3,029.34
- Trade Receivables	1,764.24	2,072.01
- Cash & Bank Balances	189.11	387.43
- Other Financial Assets	10.23	30.91
Other Current Assets	372.36	384.64
(B)	6,592.71	6,183.97
TOTAL (A + B)	15,553.03	14,536.20
EQUITY AND LIABILITIES		
Equity		
Equity Share Capital	1,535.52	1,373.18
Other Equity	12,955.22	11,746.37
(A)	14,490.74	13,119.55
Current liabilities		
Financial Liabilities		
- Borrowings	-	82.47
- Trade Payables	400.74	765.92
- Other Financial Liabilities	265.53	119.32
Provisions	94.36	81.06
Current Tax Liabilities [Net]	186.89	196.56
Other Current Liabilities	114.77	171.32
(B)	1,062.29	1,416.65
TOTAL (A+B)	15,553.03	14,536.20

For and on behalf of the Board of Directors


Mukund Mehta
Managing Director



Place: Mumbai

Dated: 7th November, 2018